In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Matinas BioPharma (MTNB - Research Report), with a price target of $3.00. The company's shares opened today at $0.85.According to TipRanks, McCarthy is an analyst with an average return of -38.2% and a 14.81% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, Daré Bioscience, and Capricor Therapeutics.Currently, the analyst consensus on Matinas BioPharma is a Strong Buy with an average price target of $3.00, implying a 252.94% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $3.
https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-matinas-biopharma-mtnb?utm_source=advfn.com&utm_medium=referral